<--- Back to Details
First PageDocument Content
Rare diseases / BirtHoggDub syndrome / Folliculin / Lymphangioleiomyomatosis / Cancer syndrome / Chromophobe cell / Pneumothorax / Renal cell carcinoma / Fibrofolliculoma / Trichodiscoma / Birt / BHD
Date: 2011-03-17 20:08:21
Rare diseases
BirtHoggDub syndrome
Folliculin
Lymphangioleiomyomatosis
Cancer syndrome
Chromophobe cell
Pneumothorax
Renal cell carcinoma
Fibrofolliculoma
Trichodiscoma
Birt
BHD

Birt-Hogg-Dubé syndrome: diagnosis and management

Add to Reading List

Source URL: www.bhdsyndrome.org

Download Document from Source Website

File Size: 653,23 KB

Share Document on Facebook

Similar Documents

Microsoft Word - AJP Jul16 PR Yue FINAL.docx

Microsoft Word - AJP Jul16 PR Yue FINAL.docx

DocID: 1qQbV - View Document

Birt-Hogg-Dubé syndrome: diagnosis and management

Birt-Hogg-Dubé syndrome: diagnosis and management

DocID: 1ovL7 - View Document

The LAM Foundation 2014 Lymphangioleiomyomatosis International Research Conference

DocID: 1lxHf - View Document

In renal transplant patients at high-immunologic risk •	 Rapamune and Cyclosporine Combination Therapy (for the first 12 months post-transplantation): One loading dose of up to 15 mg on day 1, followed by daily mainten

In renal transplant patients at high-immunologic risk • Rapamune and Cyclosporine Combination Therapy (for the first 12 months post-transplantation): One loading dose of up to 15 mg on day 1, followed by daily mainten

DocID: 1lhSD - View Document

Articles  Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

Articles Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

DocID: 1eEee - View Document